It is important to remember that mutations leading to JAK-STAT pathway activation have been previously described in solid tumors such as head and neck squamous cell carcinomas, hepatitis B associated hepatocellular carcinomas, gastric adenocarcinomas, prostate cancer, nonsmall cell lung cancer, and glioblastomas.18 This evidence concerns the gene SOAT1 and head and neck squamous cell carcinoma.